-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Baike Biopharmaceuticals issued an announcement that it plans to IPO and list on the Science and Technology Innovation Board.
The number of the company’s public offering of shares this time is 41,284,100 shares, accounting for approximately 10.
00% of the post-issuance share capital; the original shareholders of this issuance will not conduct a public offering Shares
.
After the issuance, the total share capital will be 413 million shares
The sponsor will arrange for the relevant subsidiary CITIC Securities Investment Co.
It is reported that the net profit attributable to the owners of the parent company in 2018, 2019 and 2020 of Baike Bio will be 128 million yuan, 221 million yuan and 418 million yuan, respectively
The funds raised by Baike Biology intend to invest in the following projects: 182 million yuan will be used in Changchun Baike Biotechnology Co.